Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. develops clinical-stage protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Company news centers on the rinvatercept (KER-065) program for neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, as well as elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Recurring updates include clinical data presentations, research collaborations, business highlights, financial results, and licensing economics tied to Takeda. Keros also reports governance changes, corporate presentations, portfolio prioritization, and capital actions such as its completed common-stock tender offer and capital return program.
Keros Therapeutics (Nasdaq: KROS) reported a net loss of $28.7 million for the quarter ended June 30, 2026, compared to a net loss of $30.7 million a year earlier. The company highlighted initiation of a Phase 2 trial of rinvatercept in Duchenne muscular dystrophy (DMD), with initial data expected in the first half of 2027.
Research and development expenses declined to $22.3 million from $43.5 million, and general and administrative expenses fell to $8.6 million from $14.5 million, mainly due to the transition of elritercept expenses to Takeda and a 2025 restructuring. Revenue was $0 in the quarter versus $18.2 million in 2025. Cash and cash equivalents were $257.6 million, and Keros expects this to fund operations into the first half of 2028.
Keros Therapeutics (Nasdaq: KROS) announced it will receive a $20 million development milestone payment from partner Takeda under the global license agreement for elritercept, triggered by first patient dosing in the Phase 3 ELRiSE MDS trial comparing elritercept to epoetin alfa in anemia due to certain myelodysplastic syndromes.
According to Keros, the Takeda license, effective January 16, 2025, included a $200 million upfront payment and eligibility for development, commercial and sales milestones potentially exceeding $1.1 billion, plus tiered royalties on net sales. Keros expects to distribute 25% of the net cash proceeds from this milestone payment to stockholders.
Keros Therapeutics (Nasdaq: KROS) appointed Anne Prener, M.D., Ph.D. to its Board of Directors, effective July 1, 2026. Keros is a clinical-stage biopharma company developing therapeutics targeting dysfunctional TGF-ß signaling.
Dr. Prener brings CEO, hematology, and R&D leadership experience from multiple biotech and pharma roles.
Keros Therapeutics (Nasdaq: KROS) announced that President and CEO Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. ET.
A live audio webcast will be available via Goldman Sachs and an archived replay will be accessible in the Investors section of the Keros website for up to 90 days.
Keros Therapeutics (Nasdaq: KROS) reported first quarter 2026 results and a key pipeline update. Net loss was $23.7 million, versus net income of $148.5 million a year earlier, mainly reflecting 2025 Takeda license revenue and lower research and development activity.
R&D expenses fell to $16.1 million from $48.7 million, and G&A expenses were $10.1 million versus $10.5 million. Cash and cash equivalents were $281.5 million, expected to fund operations into the first half of 2028. Partner Takeda plans a Phase 3 trial of elritercept in anemia in myelofibrosis.
Keros Therapeutics (Nasdaq: KROS) presented additional Phase 1 clinical data for rinvatercept (KER-065) at the 2026 MDA Clinical & Scientific Conference on March 9, 2026. Findings in healthy volunteers showed tolerability, body composition changes, and proteomic evidence of target engagement guiding development for DMD and ALS.
Key takeaways: generally well-tolerated with no dose-limiting toxicities or serious adverse events; increases in muscle mass and bone mineral density; decreases in fat mass; proteomic signals consistent with activin/myostatin inhibition, anti-fibrotic and anti-inflammatory effects.
Keros Therapeutics (Nasdaq: KROS) entered an agreement on March 9, 2026, with Massachusetts General Hospital to design a Phase 2 clinical trial evaluating rinvatercept in ALS patients under the Healey ALS MyMatch program.
The collaboration will use biomarker-driven, personalized trial methods to match ALS subgroups to experimental therapies and to identify optimal populations for later-stage trials.
Keros (Nasdaq: KROS) reported fourth-quarter 2025 net loss of $23.5M and full-year 2025 net income of $87.0M, driven largely by revenue from a license agreement with Takeda. The company expects to start a Phase 2 trial of rinvatercept in DMD in Q2 2026 and to engage regulators on an ALS Phase 2 design in H2 2026. Cash and cash equivalents were $287.4M at year-end, with management saying this funding is expected to support operations into the first half of 2028.
Keros Therapeutics (Nasdaq: KROS) appointed Charles Newton to its Board of Directors, effective March 9, 2026, and announced that Carl Gordon, Ph.D., CFA, will step down as director effective the same date.
Mr. Newton joins with healthcare finance and capital markets experience, including service as CFO of Lyell through September 2025 and current board roles at Novavax and Coherus Oncology.
Keros Therapeutics (Nasdaq: KROS) announced that CEO Jasbir S. Seehra, Ph.D., will present at three healthcare conferences in late February and March 2026: Oppenheimer (Feb 25), TD Cowen (Mar 3) and Leerink Partners (Mar 10).
Each presentation format is listed (corporate presentation or fireside chat) and archived replays will be available on the company investor website for up to 90 days after each event.